These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3395557)

  • 1. A negative phase II trial methylene dimethane sulphonate in advanced ovarian cancer (Cancer Research Campaign Phase I/II Trials Committee).
    Smith DB; Lind MJ; Kaye SB; Newlands ES; Blackledge GR; Gibson A
    Br J Cancer; 1988 May; 57(5):512-3. PubMed ID: 3395557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of methylene dimethane sulfonate.
    Smith DB; Fox BW; Thatcher N; Steward WP; Scarffe JH; Wagstaff J; Vezin R; Crowther D
    Cancer Treat Rep; 1987 Sep; 71(9):817-20. PubMed ID: 3621213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of methylene dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult. A study of the EORTC Soft Tissue and Bone Sarcoma Group.
    Steward WP; Mouridsen HT; Kerbrat P; Somers R; Verweij J; Van Oosterom AT; Blackledge G; Havsteen H; Thomas D; Sylvester R
    Eur J Cancer Clin Oncol; 1989 Aug; 25(8):1251-3. PubMed ID: 2767113
    [No Abstract]   [Full Text] [Related]  

  • 4. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
    Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
    Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of cytembena (NSC-104801) in patients with advanced ovarian carcinoma resistant to alkylating agents: brief communication.
    Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
    J Natl Cancer Inst; 1977 Dec; 59(6):1619-20. PubMed ID: 579188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
    Hochster H; Plimack ER; Runowicz CD; Speyer J; Wallach RC; Sorich J; Mandeli J; Wadler S; Wright J; Muggia FM
    J Clin Oncol; 2004 Jan; 22(1):120-6. PubMed ID: 14701774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
    Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
    J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.
    Kane R; Harvey H; Andrews T; Bernath A; Curry S; Dixon R; Gottlieb R; Kukrika M; Lipton A; Mortel R; Ricci J; White D
    Cancer Treat Rep; 1979 Feb; 63(2):307-9. PubMed ID: 109201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
    Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
    Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    O'Reilly S; Fleming GF; Barker SD; Walczak JR; Bookman MA; McGuire WP; Schilder RJ; Alvarez RD; Armstrong DK; Horowitz IR; Ozols RF; Rowinsky EK
    J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study.
    Lhommé C; Kerbrat P; Lejeune C; Guastalla JP; Fumoleau P; Goupil A; Héron JF; Cassin MA; Pruvot I; Soares JA; Chazard M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):48-54. PubMed ID: 8941410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of mitoxantrone in epithelial ovarian cancer.
    Lawton F; Blackledge G; Mould J; Latief T; Watson R; Chetiyawardana AD
    Cancer Treat Rep; 1987 Jun; 71(6):627-9. PubMed ID: 3581101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of doxifluridine in advanced colorectal adenocarcinoma.
    Abele R; Alberto P; Kaplan S; Siegenthaler P; Hofmann V; Ryssel HJ; Hartmann D; Holdener EE; Cavalli F
    J Clin Oncol; 1983 Dec; 1(12):750-4. PubMed ID: 6230419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
    Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
    Sorbe B; Graflund M; Nygren L; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
    Int J Oncol; 2012 Mar; 40(3):773-81. PubMed ID: 22159569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sensitivity of HeLa and Chinese hamster (ovary) cells to methylene dimethane sulphonate.
    Nias AH; Fox BW
    Chem Biol Interact; 1976 Jul; 14(1-2):93-9. PubMed ID: 182391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
    BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.